Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. - sprookjes - yvandenbroek - TriplyDB

Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

http://www.wikidata.org/entity/Q34252901

about

Phosphodiesterase 4D regulates baseline sarcoplasmic reticulum Ca2+ release and cardiac contractility, independently of L-type Ca2+ current Therapeutic potential of PDE modulation in treating heart disease Phosphodiesterases and cardiac cGMP: evolving roles and controversies Molecular inotropy mediated by cardiac miR-based PDE4D/PRKAR1α/phosphoprotein signaling Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.Compartmentalization of beta-adrenergic signals in cardiomyocytes.Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart Clinical and molecular genetics of the phosphodiesterases (PDEs).Biochemical and molecular aspects of vascular adrenergic regulation of blood pressure in the elderly Phosphodiesterases and cyclic GMP regulation in heart muscle.Compartmentation of cAMP signalling in cardiomyocytes in health and disease.The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload.Mapping the in vitro interactome of cardiac sodium (Na(+) )-calcium (Ca(2+) ) exchanger 1 (NCX1).Phosphodiesterase 1: A Unique Drug Target for Degenerative Diseases and Cognitive Dysfunction.Homology modeling, docking studies and molecular dynamic simulations using graphical processing unit architecture to probe the type-11 phosphodiesterase catalytic site: a computational approach for the rational design of selective inhibitors.Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats.cGMP Signaling in the Cardiovascular System-The Role of Compartmentation and Its Live Cell Imaging.

P2860

Q24337525-CB3D8E49-E8F5-4C6B-B7F7-B91520D85EB4 Q27005761-529EA0D2-D181-4753-A902-8E2E4F4BEFE0 Q27692588-277E1EEC-2F09-4FF4-94DF-D91A80F7F852 Q30828261-13A7DFBF-5DC2-40D7-B2FC-B4F67A2CEFAF Q33966155-26C6547D-640D-446F-A389-163183897D75 Q36270020-FD5528D7-1F0B-4FAE-83FF-ACCAC542759C Q36384788-2F01DD06-BE94-4F76-80A2-61613ACB0DF6 Q36503940-AC34C03A-5CEF-4424-8FB4-3FEBCB650FB2 Q36630526-47C19759-34ED-442C-8525-9921BC9A7B6F Q37657841-17A55C32-FED6-4478-930D-DDF6BEFD5014 Q37941005-8E5CD190-EF0B-47A7-AC10-E3D95142F343 Q38033089-EFCE1813-C679-44BD-BCDC-6740474457FA Q38079253-326339C5-9BCB-4179-8DB7-DDC608700A41 Q38123147-C08B4098-271B-4F7C-A694-8850D25EBB27 Q38650004-AD5C2F46-9990-4EA8-9EB4-B986B9EEB0D7 Q42515895-17E3915B-8946-4562-AEB8-CC6053BF4FDA Q47985759-2CF2A5FC-0889-4821-97F4-AA1F4AC33854 Q51360501-AAF1D170-376B-46C9-A3FD-868006A9EE53 Q55004774-35B6A664-0376-401B-B6B5-B3D9FE050D75

P2860

Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

http://www.wikidata.org/entity/Q34252901

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

@ast

Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

@en

Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

@nl

type

label

Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

@ast

Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

@en

Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

@nl

prefLabel

Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

@ast

Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

@en

Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

@nl

P1433

Q34252901-0EF43189-12B3-450E-904E-269970DA1AB4

P1476

Q34252901-2C42EE8E-7CC1-48BC-9CD3-6A337C6A1510

P2093

Q34252901-800AC4DB-3072-4123-A483-60BFD143251E

Q34252901-B4258831-65C6-45A4-907D-D9C49C4B44B2

P2860

Q34252901-01A47C62-CA1A-436E-B6A2-418A6C5B7D79

Q34252901-01B2BAE5-981E-41C7-B30F-8575BB93BA8B

Q34252901-02664C25-06DF-400F-AAE4-5171EC5BE598

Q34252901-074FB606-730A-4B98-ACF7-921D53B320A8

Q34252901-0A8C1544-0E2F-417D-9D4D-448D5AA33CC2

Q34252901-0AA71312-2E55-4F5A-978B-C6A033ECD868

Q34252901-0C4C7392-85BF-4B3C-8EFF-6299CF246762

Q34252901-0E333C18-1F90-40F6-A7ED-33AFC40D377A

Q34252901-0FC4366F-00DE-4751-9D3D-2736D7412F0E

Q34252901-13C61250-B6DA-4137-9E29-6223DBE9FCC8

P2888

Q34252901-8BA4E47D-7540-42B3-8040-11DFA62F738E

P304

Q34252901-CCD8379B-7CDC-48C9-B7C1-BAA2F8C91AF0

P31

Q34252901-40AC1C36-BE58-42F7-BB93-2C6E050D940C

P356

Q34252901-62123EB0-3B98-4A8D-AEFD-9332C6C42F27

P407

Q34252901-F141B3C0-2FB9-4F51-8C7A-E7DF43FC4D80

P433

Q34252901-61D65CAD-2DEE-47DC-9454-893825311847

P478

Q34252901-2C61BFC4-674F-4667-A504-7180DE78A1DA

P577

Q34252901-76B5F94D-E5BA-46C8-A936-63F981DCA3CC

P5875

Q34252901-7B06076E-2A4F-4947-AA22-C42C2BF2A42F

P6179

Q34252901-81042188-690D-4D06-A2F1-D873CA964684

P698

Q34252901-633FB512-826A-4FAB-95FC-7DB610BBAA80

P932

Q34252901-5E6D1FDA-79E9-4AC0-A282-18631174253A

P356

S12265-010-9203-9

P1433

Journal of Cardiovascular Translational Research

P1476

Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.

@en

P2093

Chen Yan

http://www.w3.org/2001/XMLSchema#string

Clint L Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases

Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias

PDE1B2 regulates cGMP and a subset of the phenotypic characteristics acquired upon macrophage differentiation from a monocyte.

cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes

Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors.

FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart

Local response of L-type Ca(2+) current to nitric oxide in frog ventricular myocytes

Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes

P2888

s12265-010-9203-9

P304

507-515

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12265-010-9203-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45189446

http://www.w3.org/2001/XMLSchema#string

P6179

1005621731

http://www.w3.org/2001/XMLSchema#string

P698

20632220

http://www.w3.org/2001/XMLSchema#string

P932

2966469

http://www.w3.org/2001/XMLSchema#string